Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT in Lung Cancer
Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/10/1/26 |
| _version_ | 1811300258543566848 |
|---|---|
| author | Kalevi Kairemo Elmer B. Santos Homer A. Macapinlac Vivek Subbiah |
| author_facet | Kalevi Kairemo Elmer B. Santos Homer A. Macapinlac Vivek Subbiah |
| author_sort | Kalevi Kairemo |
| collection | DOAJ |
| description | Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized using 3′-deoxy-3′[(18)F]-fluorothymidine (<sup>18</sup>F-FLT) PET/CT. The superiority of <sup>18</sup>F-FLT PET/CT over <sup>18</sup>F-FDG PET/CT in early therapeutic monitoring has been well described in patients after chemotherapy, radiotherapy, and/or chemo/radiotherapy. In thispilot study, we explorethe use of <sup>18</sup>F-FLT PET/CT as an early response evaluation modality in patients with lung cancerand provide specific case studies of patients with small cell lung cancer and non-small cell lung cancer who received novel targeted therapies. Early response for c-MET inhibitor was observed in four weeks and for MDM2 inhibitor in nine days. |
| first_indexed | 2024-04-13T06:48:24Z |
| format | Article |
| id | doaj.art-71c61b9b2d2648ab9ccbd7e54bf60890 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-04-13T06:48:24Z |
| publishDate | 2020-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-71c61b9b2d2648ab9ccbd7e54bf608902022-12-22T02:57:29ZengMDPI AGDiagnostics2075-44182020-01-011012610.3390/diagnostics10010026diagnostics10010026Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT in Lung CancerKalevi Kairemo0Elmer B. Santos1Homer A. Macapinlac2Vivek Subbiah3Department of Nuclear Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Nuclear Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Nuclear Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USAInvestigational Cancer Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USAAlthough 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized using 3′-deoxy-3′[(18)F]-fluorothymidine (<sup>18</sup>F-FLT) PET/CT. The superiority of <sup>18</sup>F-FLT PET/CT over <sup>18</sup>F-FDG PET/CT in early therapeutic monitoring has been well described in patients after chemotherapy, radiotherapy, and/or chemo/radiotherapy. In thispilot study, we explorethe use of <sup>18</sup>F-FLT PET/CT as an early response evaluation modality in patients with lung cancerand provide specific case studies of patients with small cell lung cancer and non-small cell lung cancer who received novel targeted therapies. Early response for c-MET inhibitor was observed in four weeks and for MDM2 inhibitor in nine days.https://www.mdpi.com/2075-4418/10/1/26<sup>18</sup>f-flt<sup>18</sup>f-flt pet/ctlung cancerresponse to therapysmall cell lung cancernon-small cell lung cancer |
| spellingShingle | Kalevi Kairemo Elmer B. Santos Homer A. Macapinlac Vivek Subbiah Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT in Lung Cancer Diagnostics <sup>18</sup>f-flt <sup>18</sup>f-flt pet/ct lung cancer response to therapy small cell lung cancer non-small cell lung cancer |
| title | Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT in Lung Cancer |
| title_full | Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT in Lung Cancer |
| title_fullStr | Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT in Lung Cancer |
| title_full_unstemmed | Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT in Lung Cancer |
| title_short | Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT in Lung Cancer |
| title_sort | early response assessment to targeted therapy using 3 deoxy 3 18 f fluorothymidine sup 18 sup f flt pet ct in lung cancer |
| topic | <sup>18</sup>f-flt <sup>18</sup>f-flt pet/ct lung cancer response to therapy small cell lung cancer non-small cell lung cancer |
| url | https://www.mdpi.com/2075-4418/10/1/26 |
| work_keys_str_mv | AT kalevikairemo earlyresponseassessmenttotargetedtherapyusing3deoxy318ffluorothymidinesup18supffltpetctinlungcancer AT elmerbsantos earlyresponseassessmenttotargetedtherapyusing3deoxy318ffluorothymidinesup18supffltpetctinlungcancer AT homeramacapinlac earlyresponseassessmenttotargetedtherapyusing3deoxy318ffluorothymidinesup18supffltpetctinlungcancer AT viveksubbiah earlyresponseassessmenttotargetedtherapyusing3deoxy318ffluorothymidinesup18supffltpetctinlungcancer |